TaiMed Biologics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TaiMed Biologics, Inc.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.
Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.